BCA
CRSP icon

Bay Colony Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Bay Colony Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,989
Closed -$215K – 440
2024
Q2 		$215K Sell
3,989
-186
-4% -$10.8K 0.04% 374
2024
Q1 		$285K Sell
4,175
-758
-15% -$54.3K 0.05% 298
2023
Q4 		$309K Sell
4,933
-1,950
-28% -$108K 0.06% 269
2023
Q3 		$312K Sell
6,883
-125
-2% -$6.46K 0.08% 231
2023
Q2 		$393K Sell
7,008
-62
-0.9% -$3.52K 0.1% 191
2023
Q1 		$312K Sell
7,070
-100
-1% -$4.86K 0.08% 224
2022
Q4 		$291K Sell
7,170
-200
-3% -$10.6K 0.08% 251
2022
Q3 		$482K Hold
7,370
– – 0.14% 153
2022
Q2 		$553K Buy
7,370
+1,600
+28% +$94.1K 0.14% 157
2022
Q1 		$362K Buy
5,770
+498
+9% +$31.3K 0.09% 231
2021
Q4 		$400K Buy
5,272
+1,301
+33% +$114K 0.11% 217
2021
Q3 		$444K Sell
3,971
-28
-0.7% -$3.52K 0.15% 186
2021
Q2 		$647K Hold
3,999
– – 0.22% 133
2021
Q1 		$487K Buy
3,999
+1,429
+56% +$216K 0.19% 152
2020
Q4 		$393K Sell
2,570
-1,225
-32% -$145K 0.21% 150
2020
Q3 		$317K Buy
3,795
+745
+24% +$66.1K 0.2% 159
2020
Q2 		$224K Buy
+3,050
New +$178K 0.16% 172
2020
Q1 		– Sell
-3,950
Closed -$231K – 186
2019
Q4 		$231K Sell
3,950
-1,000
-20% -$54.6K 0.15% 229
2019
Q3 		$203K Hold
4,950
– – 0.14% 237
2019
Q2 		$233K Sell
4,950
-950
-16% -$38K 0.15% 184
2019
Q1 		$206K Buy
+5,900
New +$204K 0.14% 192

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Bay Colony Advisors's CRSP Position: Q3 2024 in Review

Bay Colony Advisors sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 3,989 shares — an estimated $215K sold.

Bay Colony Advisors first reported a position in CRSP in Q1 2019 and held it in 21 quarters. The position peaked at $647K in Q2 2021. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

  • Bay Colony Advisors reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Bay Colony Advisors sold 3,989 CRISPR Therapeutics shares in Q3 2024, an estimated $215K.
  • Bay Colony Advisors first reported a position in CRISPR Therapeutics in Q1 2019 and held it in 21 quarters.
  • Bay Colony Advisors's CRISPR Therapeutics position peaked at $647K in Q2 2021.
  • 416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Bay Colony Advisors's 13F filing for Q3 2024, filed 24 Oct 2024.